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BACKGROUND
Polycystic ovaries (PCO) are described on ultrasound
scan as the “presence of 12 or more follicles in each
ovary measuring 2–9 mm in diameter, and/or
increased ovarian volume (>10 ml)”1. Polycystic
ovarian syndrome (PCOS) or disease (PCOD) is
diagnosed when polycystic ovaries are associated with
chronic anovulation and clinical and/or biochemical
androgen excess (typically featured as oligo-
amenorrhoea and hirsutism/acne, respectively). The
Rotterdam criteria1 for diagnosis require any two of
the three features. Unilaterality does not affect diagnosis;
neither does the location of  the cysts in the ovary.
PCOS is associated with infertility, as well as obesity,
insulin resistance and hyperinsulinaemia, leading to
impaired glucose tolerance 1. Obesity and
hyperinsulinaemia individually result in increased
androgen production1. In most women, management
includes lifestyle modifications towards weight loss.
Oral hypoglycaemic agents help to improve insulin
sensitivity; some women start to have regular periods
with the use of  metformin only2.  PCOS is a diagnosis
of medical interest, as associations with important non-
communicable diseases have been made—notably, the
metabolic syndrome. This comprises: insulin resistance,
obesity, hypertension and dyslipidaemia, which
significantly increase the woman’s risk of
cardiovascular disease3. This makes the evaluation of
PCOS in the study environment of a wider interest
beyond infertility.
Prevalence of polycystic ovarian syndrome is up to
10-26% of reproductive age group women in the
Western world4,5, but only 0.6% of  reproductive age-
group gynaecological cases was reported from
Nigeria6. Polycystic ovaries (PCO) were seen on
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ultrasound scans in 33% of the previously referenced
population in which 26% were diagnosed with PCOS5.
This study aimed to document the prevalence of
polycystic ovaries amongst women who had
gynaecological ultrasound scans at an ultrasound
diagnostic centre in Ibadan, Nigeria.
METHODS
This was a retrospective review of  671 gynaecological
transvaginal scans (TVS) performed over a year at a
female-reproductive health ultrasound diagnostic centre
in Ibadan, Nigeria. All obstetric TVSs were excluded.
All scans were performed with a 5.0 MHz or 6.0 MHz
transvaginal probe (Hitachi Aloka Medical Ltd., Tokyo,
Japan and Chison Medical Imaging Co. Ltd., Wuxi
City, Jiang Su Province, China, respectively). Probes
were sheathed in lubricated latex condoms before use.
Data were analysed with IBM SPSS Statistics 20 by
simple frequencies and means.
RESULTS
One hundred and five clients had polycystic ovaries
by the Rotterdam definition1; a proportion of 15.6%.
Most of these clients were in the 20-29 years’ age range,
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Lower abdominal pain 6 (5.7)
Uterine/ovarian assessment 19 (18.1)
To rule out pregnancy 6 (5.7)
Dysfunction uterine bleeding 4 (3.8)
Table 1: Indications for gynaecological transvaginal
scan
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with a mean age of  27.6 ± 5.7 years. Infertility (37.1%)
was the most common indication for the TVS,
followed by oligo-amenorrhoea (29.6%). Table 1
shows the indications. Fifty-seven (54.3%) women had
unilateral polycystic ovaries; the rest (45.7%) had
bilateral. Data on hyperandrogenism were not
collected, however, using the available features of the
Rotterdam criteria (PCO morphology and oligo-
amenorrhoea), at least 31 (29.5%) of these clients have
PCOS.
DISCUSSION
About a sixth of the women in this series had polycystic
ovaries, while a third fulfilled the limited available
criteria for PCOS. This indicates that the syndrome
may be more common than was previously diagnosed
in the study environment6. The significance of this is
not known. A limitation of previous assessment might
have been due to the use of the transabdominal
ultrasound route, which is not as sensitive as the
transvaginal probe for evaluating the pelvis; and
particularly the ovary. This will suggest that PCO
prevalence has not necessarily increased; but rather the
sensitivity of the diagnostic measure improved. If,
however, the prevalence did increase, it may be due to
an association with an increase in obesity and
impairment of  glucose intolerance that is emerging in
the study environment. Lifestyle changes have occurred
over the years: modern occupations are more sedentary,
more people have cars and therefore walk less, and
there is a surge in availability of fast food outlets and
increase in refined sugar in diet. Obesity is not the cause
of  PCOS, of  course; however, simple obesity is also
associated with insulin resistance, and can therefore
initiate the cascade of hyperinsulinaemia, excess
androgen production and anovulation7. It has been
suggested that the presence of  polycystic ovaries alone
should alert clinicians to advise women to avoid weight
gain, which causes a worsening of the syndrome and
greater long term morbidity8.
The review identifies PCO morphology, which does
not always translate into PCOS—its interpretation is
thus limited. As a follow-up to this, the authors are
currently prospectively evaluating associations of  PCO,
and it is hoped that this would contribute to the
knowledge of  the epidemiology in the study
environment.
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